DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic fabry disease

Clicks: 1
ID: 314226
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #64 of 96 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Residual proteinuria remains a major determinant of renal disease progression in Fabry disease (FD) despite optimized enzyme replacement or chaperone therapy and maximal renin-angiotensin system (RAS) blockade. Dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonists exert anti-inflammatory, natriuretic, and antifibrotic effects beyond metabolic control. We evaluated the impact of add-on tirzepatide on residual proteinuria in overweight, non-diabetic Fabry patients receiving optimized background therapy. METHODS: In this prospective, proof-of-concept observational study, 15 FD patients with persistent proteinuria ≥ 0.5 g/24 h despite stable disease-specific therapy and maximal tolerated RAS blockade were treated with tirzepatide for 6 months. The primary endpoint was change in 24-hour proteinuria. Secondary endpoints included change in estimated glomerular filtration rate (eGFR), body mass index (BMI), cardiac biomarkers (NT-proBNP, high-sensitivity troponin T), and safety. RESULTS: Tirzepatide is associated with a progressive reduction in proteinuria, which became statistically significant at Month 1 and continued through Month 6 (1.11 ± 0.23 g/24 h at baseline to 0.35 ± 0.19 g/24 h at 6 months; 68.9% reduction; P < 0.001). Two-thirds of patients (66.7%) achieved proteinuria < 0.5 g/24 h. eGFR remained stable throughout the treatment period (P = 0.87). Tirzepatide induced significant weight loss, with BMI decreasing from 29.0 (27.1-29.3) kg/m² at baseline to 24.2 (23.4-25.1) kg/m² at Month 6 (P < 0.001). Beyond the renal effects, cardiac biomarkers also showed significant reductions, with NT-proBNP and high-sensitivity troponin T decreasing by 33.3% (P < 0.01) and 14.3% (P < 0.05), respectively, in the absence of structural echocardiographic changes, that may reflect early modulation of myocardial stress. The drug was well tolerated, with mild gastrointestinal symptoms during initial dose titration and no treatment discontinuations. CONCLUSIONS: Add-on dual GIP/GLP-1 receptor agonism is associated with a reduction in residual proteinuria and showed improvements in cardiac biomarkers in overweight Fabry patients receiving optimized therapy, without affecting eGFR. These findings support a multi-pathway nephroprotective strategy beyond substrate reduction and RAS inhibition.
Reference Key
openalex_W7161752017 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eleonora Riccio, Alessandra Cuomo, Ivana Capuano, Letizia Spinelli, G I Guido Iaccarino, Oriana De Marco, Antonio Pisani
Journal nephrology dialysis transplantation
Year 2026
DOI
10.1093/ndt/gfag115
URL
https://doi.org/10.1093/ndt/gfag115
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.